Company
Bristol Myers Squibb
Official Name: Bristol-Myers Squibb Company
Headquarters: New York, NY, United States
Founded: 1887
Employees: 32,200
CEO: Dr. Giovanni Caforio M.D.
Market Cap
$130.84 Billion
USD as of July 1, 2023
Bristol Myers Squibb Categories
United States
languages
Healthcare
languages
Drug Manufacturers—General
United States Healthcare
United States Drug Manufacturers—General
Company Description
Bristol Myers Squibb Company, also known as BMS, is a multinational pharmaceutical company. Tracing its origins to1858, it develops and manufactures prescription pharmaceuticals and biologics for a diverse range of diseases including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders.
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—General
| Company | Market Cap (USD) |
|---|---|
|
Lilly
|
$417.05 B |
|
Johnson & Johnson
|
$412.24 B |
|
Merck
|
$275.82 B |
Roche
|
$241.08 B |
|
AbbVie
|
$239.18 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
|
UnitedHealth Group
|
$428.70 B |
|
Lilly
|
$417.05 B |
|
Johnson & Johnson
|
$412.24 B |
Novo Nordisk
|
$329.83 B |
|
Merck
|
$275.82 B |
Detailed Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Key People
Founder(s): William Mc Laren Bristol John Ripley Myers E. R. Squibb
Giovanni Caforio, M. D. (Chairman & CEO) David Elkins (CFO)
Financials
Revenue: US$42.518 billion (2020)
Operating income: US$30.745 billion (2020)
Net income: US$8.995 billion (2020)
Total assets: US$129.44 billion (2019)
Total equity: US$59.70 billion (2019)